2024-11-05 - Analysis Report
## AbbVie Inc. (ABBV) Stock Analysis Report

This report provides an in-depth analysis of AbbVie Inc. (ABBV) based on the given data. 

**1. Performance and Relative Performance**

**Company Overview:** AbbVie Inc. is a research-based global biopharmaceutical company that develops, manufactures, and commercializes a wide range of healthcare products. 

**Performance:**

* **Cumulative Return:** 159.82%
* **S&P 500 (VOO) Cumulative Return:** 131.28%
* **Return Difference:** 28.54%
* **Relative Divergence:** 68.98% (This means that AbbVie's performance is currently within the 68.98th percentile of its historical performance range compared to the S&P 500)

**Alpha and Beta Analysis:**

| Year | CAGR | MDD | Alpha | Beta |
|---|---|---|---|---|
| 2015 | -10.1% | 30.2% | -9.3% | 1.1 |
| 2016 | 8.7% | 15.8% | -2.7% | 0.9 |
| 2017 | 55.0% | 7.2% | 36.3% | 0.8 |
| 2018 | -6.3% | 34.1% | 0.7% | 1.1 |
| 2019 | -0.8% | 27.8% | -29.4% | 0.9 |
| 2020 | 19.6% | 33.7% | 4.5% | 0.7 |
| 2021 | 28.4% | 11.6% | -0.3% | 0.6 |
| 2022 | 19.3% | 22.4% | 39.4% | 0.3 |
| 2023 | -4.6% | 19.4% | -29.4% | 0.2 |
| 2024 | 25.4% | 14.6% | 4.8% | 0.2 |

**Analysis:**

* AbbVie has generally outperformed the S&P 500 over the past decade, with a higher cumulative return. 
* AbbVie's Alpha is generally positive, indicating that it has outperformed the market, especially in 2017 and 2022. 
* Beta has been fluctuating, indicating varying levels of volatility compared to the market.

**2. Recent Price Movements:**

* **Last Closing Price:** 200.47
* **5-day Moving Average:** 199.77
* **20-day Moving Average:** 193.04
* **60-day Moving Average:** 194.25

**Analysis:**

* The stock is trading above its 5-day, 20-day, and 60-day moving averages, indicating potential upward momentum.

**3. Technical Indicators:**

* **RSI:** 63.27 - Suggests the stock is in overbought territory, potentially indicating a short-term pullback.
* **PPO:** 0.81 - Positive PPO indicates potential upward price momentum.
* **Delta_Previous_Relative_Divergence:** 7.24 (+) - Suggests a short-term upward trend.
* **Expected Return:** 2.99% -  Indicates a potential for long-term outperformance compared to the S&P 500.

**Analysis:**

* The technical indicators suggest potential for continued upward price movement, however, the RSI being in overbought territory indicates potential for short-term correction.

**4. Recent Earnings and Outlook:**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-10-30 | 3 | 2.92 |
| 2024-07-25 | 2.65 | 2.57 |
| 2024-04-26 | 2.31 | 2.26 |
| 2024-02-02 | 2.79 | 2.76 |
| 2023-10-27 | 2.95 | 2.86 |

**Analysis:**

* AbbVie has consistently exceeded earnings expectations in the last few quarters. 
* The most recent earnings report shows strong performance, exceeding expectations by a significant margin.

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-06-30 | $14.46B | 70.94% |
| 2024-03-31 | $12.31B | 66.74% |
| 2023-12-31 | $14.30B | 60.11% |
| 2023-09-30 | $13.93B | 53.44% |
| 2023-06-30 | $13.87B | 69.42% |

**Analysis:**

* AbbVie consistently generates strong revenue and maintains a high profit margin. 
* Revenue growth is steady, while the profit margin is relatively stable.

**2) Capital and Profitability:**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-06-30 | $6.78B | 20.21% |
| 2024-03-31 | $8.01B | 17.10% |
| 2023-12-31 | $10.36B | 7.93% |
| 2023-09-30 | $12.09B | 14.70% |
| 2023-06-30 | $12.87B | 15.73% |

**Analysis:**

* AbbVie maintains a strong capital position and a healthy ROE, indicating efficient use of shareholder equity.

**6. News and Recent Events:**

* **Earnings News:** Analyze recent earnings calls and press releases for insights into AbbVie's performance, future growth plans, and any potential challenges. 
* **Market Outlook:** Research recent market reports and analyst opinions on AbbVie's future prospects, focusing on factors such as market competition, regulatory landscape, and potential new drug launches.
* **Performance Highlights:** Review articles and news pieces highlighting AbbVie's recent achievements and performance milestones.

**7. Comprehensive Analysis:**

* AbbVie Inc. is a financially sound company with a history of strong performance. 
* Recent earnings have been positive, and the stock is trading with potential upward momentum. 
* Technical indicators suggest a short-term correction could be in the near future, but long-term prospects remain positive. 
* AbbVie's continued focus on research and development, new drug launches, and robust financial performance positions it well for continued growth in the long term.

**8. Conclusion:**

Based on the available data, AbbVie Inc. (ABBV) appears to be a promising investment for long-term growth. The company demonstrates strong financial health, consistent outperformance compared to the market, and a track record of exceeding earnings expectations. However, investors should be aware of the potential for short-term corrections due to the current overbought condition indicated by the RSI. 

**Disclaimer:** This report is intended for informational purposes only and should not be construed as financial advice. Investors are advised to conduct their own thorough research before making any investment decisions. 
